Kept an ocean away from its scientific advisors, Shanghai's Elpiscience keeps up the clinical progress, refuels for its I/O pipeline
When Elpiscience pooled $100 million for its Series B in late 2019, CEO Darren Ji promised to move what he described as one of the broadest immuno-oncology pipelines swiftly through the clinic in both the US and China.
Then a pandemic got in the way — but not by much. The Shanghai-based biotech managed to keep testing its 4-1BB/PD-L1 drug, get an OX40 agonist cleared for clinical trials (nabbing a collaboration with Junshi in the process), while in-licensing a Phase I bispecific from California’s TRIGR Therapeutics.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,100+ biopharma pros reading Endpoints daily — and it's free.